Theriva Biologics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Theriva Biologics, Inc. (TOVX) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $135.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-11
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $135.00K, a 21.97% decline year-over-year.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $135.00K, a 35.00% increase year-over-year.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $228.00K, a 28.81% increase year-over-year.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $173.00K, a 0.58% increase year-over-year.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $654.00K, a 2.53% decline from fiscal 2024.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $671.00K, a 21.56% increase from fiscal 2023.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $552.00K, a 16.21% increase from fiscal 2022.
- Theriva Biologics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $475.00K, a 14.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $135.00K 10-Q · filed 2026-08-11 | $270.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $135.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $654.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $228.00K 10-Q · filed 2025-11-12 | $401.00K derived: sum of 2 quarters · filed 2026-08-11 | $501.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $173.00K 10-Q · filed 2026-08-11 | $273.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $671.00K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $177.00K 10-Q · filed 2025-11-12 | $349.00K derived: sum of 2 quarters · filed 2025-11-12 | $509.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $172.00K 10-Q · filed 2025-11-12 | $332.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $160.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $552.00K 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $135.00K 10-Q · filed 2024-11-12 | $281.00K derived: sum of 2 quarters · filed 2024-11-12 | $407.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $146.00K 10-Q · filed 2024-11-12 | $272.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $126.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $475.00K 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $121.00K 10-Q · filed 2023-11-13 | $234.00K derived: sum of 2 quarters · filed 2023-11-13 | $346.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $113.00K 10-Q · filed 2023-11-13 | $225.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $112.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $416.00K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $102.00K 10-Q · filed 2022-11-10 | $204.00K derived: sum of 2 quarters · filed 2022-11-10 | $305.00K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $102.00K 10-Q · filed 2022-11-10 | $203.00K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $101.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $350.00K 10-K · filed 2022-03-16 | |||
| 2020-09-30 | $82.00K 10-Q · filed 2021-11-03 | $168.00K derived: sum of 2 quarters · filed 2021-11-03 | $251.00K derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $86.00K 10-Q · filed 2021-11-03 | $169.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $83.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $340.00K 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $91.00K 10-Q · filed 2020-11-10 | $182.00K derived: sum of 2 quarters · filed 2020-11-10 | $246.00K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $91.00K 10-Q · filed 2020-11-10 | $155.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $64.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $2.07M 10-K · filed 2020-02-20 | |||
| 2018-09-30 | $475.00K 10-Q · filed 2019-11-04 | $1.03M derived: sum of 2 quarters · filed 2019-11-04 | $1.71M derived: sum of 3 quarters · filed 2019-11-04 | |
| 2018-06-30 | $557.00K 10-Q · filed 2019-11-04 | $1.23M derived: sum of 2 quarters · filed 2019-11-04 | ||
| 2018-03-31 | $676.00K 10-Q · filed 2019-11-04 | |||
| 2017-12-31 | $3.41M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $4.01M 10-K · filed 2018-02-22 | |||
| 2015-12-31 | $3.20M 10-K · filed 2018-02-22 | |||
| 2014-12-31 | $2.46M 10-K · filed 2017-03-02 | |||
| 2013-12-31 | $1.67M 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $1.85M 10-K · filed 2015-03-16 | |||
| 2011-12-31 | $973.00K 10-K · filed 2013-04-16 | |||
| 2010-12-31 | $400.00K 10-K/A · filed 2012-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |